Replimune, uniQure rise; FDA commissioner Makary plans to resign

Shares of biotech firm Replimune Group REPL.O rise 14.7% to $4.2

U.S. Food and Drug Administration Commissioner Marty Makary plans to resign on Tuesday, according to two sources familiar with the situation

FDA Deputy Commissioner Kyle Diamantas will lead the agency in an acting capacity, Politico, which first reported the development, says

Last month, the health regulator declined to approve REPL's drug for the second time

U.S.-listed shares of Dutch gene therapy developer uniQure UQ1.F rise 6.1% to $29.4

FDA in March had called for a new study to support the approval of uniQure's gene therapy for the rare, inherited neurodegenerative disorder, and rejected its most recent trial for not including participants given a placebo

Shares of vaccine makers including Pfizer PFE.N and Moderna MRNA.O were up over 1%